Ross Osborn
Stock Analyst at Cantor Fitzgerald
(0.71)
# 2,851
Out of 4,412 analysts
66
Total ratings
17.65%
Success rate
-16.98%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYNZ Mainz Biomed B.V. | Reiterates: Neutral | n/a | $0.82 | - | 7 | Apr 12, 2024 | |
| AWH Aspira Women's Health | Reiterates: Neutral | $3.3 | $3.33 | -0.80% | 5 | Apr 10, 2024 | |
| PRE Prenetics Global | Maintains: Overweight | $10 → $9 | $4.61 | +95.23% | 5 | Apr 4, 2024 | |
| LUCD Lucid Diagnostics | Maintains: Overweight | $3.8 → $3 | $0.68 | +339.17% | 2 | Mar 27, 2024 | |
| SMTI Sanara MedTech | Maintains: Overweight | $49 → $44 | $32.35 | +36.01% | 3 | Mar 27, 2024 | |
| VNRX VolitionRx | Reiterates: Overweight | $2.5 | $0.91 | +173.61% | 2 | Mar 27, 2024 | |
| CERS Cerus | Reiterates: Overweight | $3 | $1.71 | +75.44% | 2 | Mar 6, 2024 | |
| NPCE NeuroPace | Maintains: Overweight | $16 → $18 | $13.39 | +34.43% | 2 | Mar 6, 2024 | |
| ORGO Organogenesis Holdings | Reiterates: Overweight | $5 | $2.35 | +112.77% | 2 | Mar 1, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $25 | $14.57 | +71.59% | 7 | Feb 27, 2024 | |
| RCEL AVITA Medical | Maintains: Overweight | $22 → $25 | $8.52 | +193.43% | 7 | Feb 23, 2024 | |
| NNOX Nano-X Imaging | Reiterates: Overweight | $18 | $8.96 | +100.89% | 4 | Feb 15, 2024 | |
| NYXH Nyxoah | Maintains: Overweight | $10 → $14 | $10.62 | +31.83% | 1 | Feb 9, 2024 | |
| AXGN AxoGen | Reiterates: Overweight | $12 | $6.63 | +81.00% | 2 | Jan 19, 2024 | |
| ASXC Asensus Surgical | Downgrades: Neutral | n/a | $0.25 | - | 3 | Nov 16, 2023 | |
| ELUT Elutia | Maintains: Overweight | $8 → $6 | $2.78 | +115.83% | 3 | Nov 14, 2023 | |
| PACB Pacific Biosciences of California | Upgrades: Overweight | $14 → $11 | $1.47 | +648.30% | 4 | Oct 31, 2023 | |
| XGN Exagen | Reiterates: Overweight | $6 | $1.41 | +324.90% | 3 | Sep 26, 2023 | |
| PAVM PAVmed | Reiterates: Neutral | $8.61 | $1.72 | +400.58% | 2 | Aug 18, 2023 |
Mainz Biomed B.V.
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.82
Upside: -
Aspira Women's Health
Apr 10, 2024
Reiterates: Neutral
Price Target: $3.3
Current: $3.33
Upside: -0.80%
Prenetics Global
Apr 4, 2024
Maintains: Overweight
Price Target: $10 → $9
Current: $4.61
Upside: +95.23%
Lucid Diagnostics
Mar 27, 2024
Maintains: Overweight
Price Target: $3.8 → $3
Current: $0.68
Upside: +339.17%
Sanara MedTech
Mar 27, 2024
Maintains: Overweight
Price Target: $49 → $44
Current: $32.35
Upside: +36.01%
VolitionRx
Mar 27, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.91
Upside: +173.61%
Cerus
Mar 6, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.71
Upside: +75.44%
NeuroPace
Mar 6, 2024
Maintains: Overweight
Price Target: $16 → $18
Current: $13.39
Upside: +34.43%
Organogenesis Holdings
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.35
Upside: +112.77%
SI-BONE
Feb 27, 2024
Maintains: Overweight
Price Target: $25
Current: $14.57
Upside: +71.59%
AVITA Medical
Feb 23, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $8.52
Upside: +193.43%
Nano-X Imaging
Feb 15, 2024
Reiterates: Overweight
Price Target: $18
Current: $8.96
Upside: +100.89%
Nyxoah
Feb 9, 2024
Maintains: Overweight
Price Target: $10 → $14
Current: $10.62
Upside: +31.83%
AxoGen
Jan 19, 2024
Reiterates: Overweight
Price Target: $12
Current: $6.63
Upside: +81.00%
Asensus Surgical
Nov 16, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.25
Upside: -
Elutia
Nov 14, 2023
Maintains: Overweight
Price Target: $8 → $6
Current: $2.78
Upside: +115.83%
Pacific Biosciences of California
Oct 31, 2023
Upgrades: Overweight
Price Target: $14 → $11
Current: $1.47
Upside: +648.30%
Exagen
Sep 26, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.41
Upside: +324.90%
PAVmed
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $1.72
Upside: +400.58%